Adheris Health Limited · ASX:AHE
Adheris Health — Shareholder Meeting (November 2023)
34 slides from Adheris Health's shareholder meeting presentation, Nov 28, 2023
Slide 1: 2023 Annual General Meeting
2023 Annual General Meeting A global leader in personalised medication management 28 November 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation is dated 28 November 2023 and has been prepared by MedAdvisor Limited ABN 17 145 This presentation should not be considered as the giving of investment advice by MedAdvisor Solutions 327 617 and its group companies (trading as MedAdvisor Solutions) f
Slide 3: How to cast a vote online
How to cast a vote online 1 When the poll is open, select the vote icon at the top of the screen 1 2A To vote, select either ‘For’, ‘Against’ or ‘Abstain’ Items of Business 2B You will see a vote confirmation 2A 2A Re-elect Mr. Sam Sample as a Director To change or cancel your vote “click here to 3
Slide 4: How to ask a question
How to ask a question 1 To ask a written question select the Q & A icon Select the topic your question relates to from the 4 1 2 drop-down list Type your question in the text box and press the 3 send button 3 To ask a verbal question follow the instructions below 4 the broadcast window 2 4 2023 Annu
Slide 5: Agenda
Agenda 1 Chair’s Address 2 CEO’s Address 3 Resolutions & Voting 4 Q&A 5 2023 Annual General Meeting
Slide 6: Chair's Address
Chair’s Address FY23 marked a period of transition as the company continued to bolster its capabilities on its pathway to profitable growth. We are delighted with outcomes of the significant changes implemented, the strategies enacted, and the advancements achieved during this pivotal phase of strat
Slide 7: Board of Directors
Board of Directors Linda Jenkinson Rick Ratliff Jim Xenos Non-Executive Chair CEO & Managing Director Non-Executive Director Sandra Hook Anthony Tassone Brett Magun Non-Executive Director Non-Executive Director Non-Executive Director Lucas Merrow Kevin Hutchinson Kate Hill Non-Executive Director Non
Slide 8: CEO's Address
CEO’s Address Our future is in our hands, as we work to achieve enduring profitable growth. Our singular purpose is to deliver innovative, data-driven, omni-channel personalised solutions intended to simplify people’s medication journey and empower the pharmacy of the future. Rick Ratliff CEO 8 2023
Slide 9: Executive Management Team
Executive Management Team Rick Ratliff Ancila Desai Vinod Subramanian CEO & Managing CFO, Chief Chief Operating Director Administrative Officer Officer and Company Secretary Jim Rotsart Brian Peterson Wayne Marinoff President — US Chief Strategy President — ANZ Officer — US 9 2023 Annual General Mee
Slide 10: MedAdvisor Solutions personalised medication management platform
MedAdvisor Solutions personalised medication management platform Delivering individualised patient engagement solutions that simplify the patients medication journey and power the pharmacy of the future. 10 2023 Annual General Meeting
Slide 11: We have built this global platform over time
We have built this global platform over time 11 2023 Annual General Meeting
Slide 12: FY23 Group Highlights
FY23 Group Highlights Continued momentum on our Pathway-to-Profitability. FY23 revenue of FY23 gross margin of $98.0M up 44.6% YOY 60.6% up from 51.6% FY22 EBITDA of ($3.0M) improved by Strong cash position of $8.3M+ All financials are in AUD, unless stated otherwise. $14.2M 12 2023 Annual General M
Slide 13: FY23 Highlights—ANZ & US
FY23 Highlights—ANZ & US Achieved strong YOY growth as the pharmacy network expanded in ANZ and the US. ANZ FY23 revenue of (including GuildLink acquisition) US FY23 revenue of $19.9M up 41.9% YOY $78.1M up 45.5% YOY ANZ FY23 gross profit of US FY23 gross profit of $16.7M up from $11.7M FY22 $42.6M
Slide 14: FY23 Pathway-to-Profitability progress
FY23 Pathway-to-Profitability progress In FY23, our Pathway-to-Profitability initiative fortified our global platform, improved our cost base, and sparked the engine for sustained profitable growth. Global Platform Business Operations Product Innovation • Migration of 1,414 GuildLink • Restructuring
Slide 15: FY24 Pathway-to-Profitability continues
FY24 Pathway-to-Profitability continues Continued focus on profitable growth. ANZ Priorities US Priorities Global platform • Finalize move of Plus One to the cloud • Complete cloud optimisation Continued development of personalized • Move data platform to the cloud • Move data platform to the cloud
Slide 16: Launching AI in the US (Proof of concept)
Launching AI in the US (Proof of concept) A Better Patient How can I help? Experience • Patient support 24/7 • Communications tailored to meet patient’s unique preferences and needs • Reduced pharmacist burden • Ability to provide better support due to “Virtual confidant phenomenon” Medication • Con
Slide 17: Expanded scope of practice in Australia
Expanded scope of practice in Australia MedAdvisor Solutions has been selected as the preferred software provider to support the 2024 – 2025 expanded scope of practice pilot. Pilot Scope (1 February, 2024 Launch): • Pharmacists will be able to diagnose and treat up to 23 everyday health conditions •
Slide 18: UK strategy is taking shape
UK strategy is taking shape We will maintain a position in the UK while lowering costs, shifting focus and creating options for expansion. Strategic Investment Strategic Rationale • Strategic investment up to £1m in a UK business, Charac • MedAdvisor Solutions and Charac are both focused on Limited
Slide 19: Our strategy going forward
Our strategy going forward Our initial 5-year strategy, developed in FY23 identified a core set of initiatives with a total addressable market of over $20B. These initiatives will be steered by the following key drivers: • Increasing patient reach and engagement • Strengthening and expanding core so
Slide 20: Strong start to FY24
Strong start to FY24 In 1Q FY24, we delivered a 27% year-over-year increase in operating revenue. 1Q Operating Revenue ($M) $25.4M 1Q FY24 Highlights • 1Q group gross profit was up 30.8% to $15.7M (1Q $20.0M FY23: $12.0M) • 1Q revenues increased in ANZ as new subscriptions from GuildLink pharmacies
Slide 21: FY24 outlook and beyond
FY24 outlook and beyond Continued momentum from 1Q to 2Q is expected to result in 1H FY24 revenue increasing by 10-15% versus a very strong 1H FY23. FY24 Market Dynamics Implications Pharma continues to invest in awareness programs to encourage vaccinations Increased focus on vaccines during the flu
Slide 22: Voting
Voting 22 2023 Annual General Meeting
Slide 23: Notice of Meeting & Voting
Notice of Meeting & Voting Notice of meeting released on 27 September 2023 and is available at https://www.medadvisorsolutions.com/en-au/investor 23 2023 Annual General Meeting
Slide 24: Annual Accounts
Annual Accounts Members should note that the Financial The Annual Report including Statements and Reports are not tabled the Financial Statements for for approval but simply discussion. the year ended 30 June 2023 and the Reports of the A representative from our auditors, RSM Directors and Auditors
Slide 25: Resolutions
Resolutions 25 2023 Annual General Meeting
Slide 26: Adoption of Remuneration Report
Resolution 1 ADOPTION OF REMUNERATION REPORT “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the remuneration report as contained in the Company’s annual report for the financial year ended 30 June 2023.” Please not
Slide 27: Re-election of Director – Mr Lucas Merrow
Resolution 2 RE-ELECTION OF DIRECTOR – MR LUCAS MERROW “That, for the purpose of clause 14.2 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Lucas Merrow, a Director, retires by rotation, and being eligible, is re-elected as a Director.” Please note that the Voting Exclusio
Slide 28: Re-election of Director – Ms Sandra Hook
Resolution 3 RE-ELECTION OF DIRECTOR – MS SANDRA HOOK “That, for the purpose of clause 14.2 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Ms Sandra Hook, a Director, retires by rotation, and being eligible, is re-elected as a Director.” Please note that the Voting Exclusion
Slide 29: Re-election of Director – Ms Kate Hill
Resolution 4 RE-ELECTION OF DIRECTOR – MS KATE HILL “That, for the purpose of clause 14.4 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Ms Kate Hill, who was appointed as a Director on 24 May 2023, retires, and being eligible, is re-elected as a Director.” Please note that t
Slide 30: Re-election of Director – Mr Brett Magun
Resolution 5 RE-ELECTION OF DIRECTOR – MR BRETT MAGUN “That, for the purpose of clause 14.4 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Brett Magun, who was appointed as a Director on 24 May 2023, retires, and being eligible, is re-elected as a Director.” Please note th
Slide 31: Approval of Long Term Incentive Plan
Resolution 6 APPROVAL OF LONG TERM INCENTIVE PLAN "That for the purpose of Listing Rule 7.2, exception 13 and for all other purposes, the Company approves the Company's Long Term incentive Plan (LTIP) and for the issue of up to 27,330,646 securities under that LTIP during a three-year period from th
Slide 32: Issue of Options to Ms Kate Hill
Resolution 7 ISSUE OF OPTIONS TO MS KATE HILL "That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue to Ms Kate Hill, 1,000,000 options exercisable on or before 31 December 2031 on the terms and conditions set out in the Explanatory S
Slide 33: Poll
Poll 33 2023 Annual General Meeting
Slide 34: Q&A 2023 Annual General Meeting
Q&A 34 2023 Annual General Meeting